Keeps donor hearts, lungs, and livers alive in warm blood during transport so organs that cold storage would discard can actually be used.
What this company is and how it runs — written from structure, not news.
TransMedics Group keeps donor hearts, lungs, and livers alive during transport by circulating warm oxygenated blood through them — rather than packing them in ice and slowing their metabolism to a halt — which means each organ must be continuously monitored by a credentialed perfusionist riding alongside it for the entire journey. Because every transport ties up one perfusionist for its full duration, the number of organs TransMedics can handle on any given day is capped by how many trained perfusionists it has available, not by how many machines it has built or how much perfusion solution it has in stock. Training a new perfusionist takes months of hands-on work during live transports and cannot be rushed, so the workforce grows slowly even when demand is there. A transplant center that adopts OCS also has to retrain its surgeons — because a warm-perfused organ looks and behaves differently on the table than a cold one — which makes switching back to cold storage costly enough that most centers stay with the system once they have integrated it.
How does this company make money?
The company charges transplant centers a per-case fee each time the OCS system is used. That fee covers the use of the machine, the organ-specific perfusion solutions and circuits consumed during the case, and the perfusionist services provided throughout the transport. There is no revenue unless a case takes place — every dollar flows from an actual organ transport.
What makes this company hard to replace?
Transplant surgeons must complete training protocols specific to OCS organ assessment and implantation, because the way a warm-perfused organ looks and behaves before implantation is different from a cold-stored organ — skills from one do not directly transfer to the other. Beyond the surgeons, each transplant center must integrate OCS equipment into its existing surgical workflows and put its broader staff through certification before the technology can be used in a live case. A center that wanted to abandon OCS and return to cold storage would lose those capabilities and the access to marginal donor organs that comes with them.
What limits this company?
Every single transport ties up one credentialed perfusionist for its entire duration. When several donor organs become available at the same time in different parts of the country, the number of available perfusionists — not the number of machines or the supply of perfusion solutions — decides how many of those organs can actually be accepted. Perfusionist certification requires extensive hands-on experience with live organ perfusion and emergency protocols, so the training pipeline cannot be sped up to meet sudden demand spikes.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance covering the OCS heart, lung, and liver platforms — if that clearance were revoked or restricted, the system could not be legally used. It also depends on organ procurement organizations, known as OPOs, to actually allocate donor organs into the OCS workflow rather than routing them to cold storage. Specialized perfusion solutions and circuits manufactured to biocompatible standards must be available for every case. Aviation partners provide the flight logistics that make nationwide transport possible. And transplant centers need OCS-trained surgical teams in place before a case can proceed.
Who depends on this company?
Transplant centers rely on the OCS platform to assess and transport marginal donor organs — the extended-criteria organs that cold storage typically discards — and would lose access to those organs if the system were unavailable. Patients with end-stage heart, lung, or liver failure who are waiting for a transplant would face a smaller pool of usable organs, because more extended-criteria donors would be turned away. Organ procurement organizations would be pushed back to traditional cold storage, which shortens the viable transport window and results in higher organ discard rates.
How does this company scale?
OCS machines and perfusion solutions can be produced in larger volumes through standard medical device manufacturing — that part of the operation can grow without unusual friction. What does not scale easily is the perfusionist network. Each new perfusionist requires extensive hands-on training during actual organ transport cases and full certification before they can run a case independently, so the qualified workforce grows slowly regardless of how much the company invests in training programs.
What external forces can significantly affect this company?
Whether Medicare and private insurers agree to reimburse OCS-preserved organ transplants directly shapes whether hospitals are willing to use the technology at all — a negative coverage decision from a major payer would reduce demand quickly. Organ allocation policy set by the United Network for Organ Sharing can change the geographic spread of procurement, which affects how often long, complex transports happen and whether the OCS model remains the obvious choice. Aviation regulations and air traffic control restrictions can disrupt or delay the flight legs that many organ transports depend on.
Where is this company structurally vulnerable?
If the United Network for Organ Sharing changed its allocation policy to concentrate organ procurement into fewer, geographically tighter regions, there would be fewer situations where an organ needs to travel far or be assessed for marginal viability in transit. Those long, complex, multi-region transports are exactly what makes warm perfusion and a deployed perfusionist network worth the cost. Fewer of those scenarios would erode the clinical and logistical case for the whole model.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three observations describe the present configuration: operating income increased year-over-year in each of the last four fiscal years, the 6-year revenue CAGR is positive, and revenue increased year-over-year in each of the last five fiscal years. None of the three observations divides by revenue.
Two observations describe the retention path: net income as a share of pretax income shows a near-zero effective tax rate, and net income as a share of EBIT shows that interest and tax together consume little of operating profit.
Where is this company structurally exposed?
Three price-behavior observations have aligned: the ulcer index (drawdown depth and duration composite) is elevated, current drawdown from peak is significant, and 20-week annualized volatility is in the upper portion of its mapped range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph